Comparative evaluation of cyclosporine A/HPβCD-incorporated PLGA nanoparticles for development of effective ocular preparations

References

• Aksungur P, Demirbilek M, Denkbaş BE, Vandervoort J, Ludwig A, Ünlü N. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: Cellulat toxicity, uptake, and kinetic studies. J Control Release 2011; 151: 286–94
   PubMed Web of Science ®Google Scholar
• Aktaş Y, Ünlü N, Orhan M, İrkeç M, Hıncal AA. Influence of hydroxypropyl-β-cyclodextrin (HPβCD) on the corneal permeation of pilocarpine. Drug Dev Ind Pharm 2003; 29: 223–30
   PubMed Web of Science ®Google Scholar
• Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: Preparation and in-vitro evaluation. Eur J Pharm Biopharm 2008; 70: 819–82
   PubMed Web of Science ®Google Scholar
• Belin WM, Bouchard CS, Phillips TM. Update on topical cyclosporin A, background, immunology and pharmacology. Cornea 1990; 9: 184–95
   PubMed Web of Science ®Google Scholar
• Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D, Ponchel G. Combined hydroxypropyl-β-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 2001; 218: 113–24
   PubMed Web of Science ®Google Scholar
• Brewster ME, Hora MS, Simpkins JW, Bodor N. Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res 1991; 8: 792–5
   PubMed Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645–66
   PubMed Web of Science ®Google Scholar
• Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 2007; 123: 78–99
   PubMed Web of Science ®Google Scholar
• Challa R, Ahuja A, Ali J, Khar RK. 2005. Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech 2005; 6: 329–57
   PubMed Web of Science ®Google Scholar
• Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev 1997; 97: 1325–57
   PubMed Web of Science ®Google Scholar
• Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm 2006; 314: 72–82
   PubMed Web of Science ®Google Scholar
• FDA, Center for Drug Evaluation and Research, Guidance for Industry. 1997. Dissolution testing of immediate release solid oral dosage forms. Rockville, USA.
   Google Scholar
• Frömming KH, Szejtli J. Cyclodextrins in pharmacy. Kluwer Academic Publishers, Dordrecht, The Netherlands 1994
   Google Scholar
• Fukaya H, Iimura A, Hoshiko K, Fuyumuro T, Noji S, Nabeshima T. A cyclosporin A/maltosyl-a-cyclodextrin complex for inhalation therapy of asthma. Eur Respir J 2003; 22: 213–19
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Trapani A, Alonso MJ. Protection of the peptide glutathione by complex formation with a-cyclodextrin: NMR spectroscopic analysis and stability study. Eur J Pharm Biopharm 2006; 64: 146–53
   PubMed Web of Science ®Google Scholar
• Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell-growth cell kill. J Immunol Methods 1989; 119: 203–10
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instr 1965; 4: 117–212
   Google Scholar
• Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 1999; 36: 101–23
   PubMed Web of Science ®Google Scholar
• Jin CY, Zhu BS, Wang XF, Lu QH. Cytotoxicity of titanium dioxide nanoparticles in mouse fibroblast cells. Chem Res Toxicol 2008; 21: 1871–87
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm 2003; 56: 307–18
   PubMed Web of Science ®Google Scholar
• Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. J Drug Target 2010; 18: 645–56
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017–25
   PubMed Web of Science ®Google Scholar
• Mannila J, Järvinen K, Holappa J, Matilainen L, Auriola S, Jarho P. Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. Int J Pharm 2009; 381: 19–24
   PubMed Web of Science ®Google Scholar
• Matilainen L, Järvinen K, Toropainen T, Näsi E, Auriola S, Järvinen T, Jarho P. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int J Pharm 2006; 318: 41–8
   PubMed Web of Science ®Google Scholar
• Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 1996; 13: 163–7
   PubMed Web of Science ®Google Scholar
• Miyake K, Hirayama F, Uekama K. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha-and-beta-cyclodextrins in aqueous solution. J Pharm Sci 1999; 88: 39–45
   PubMed Web of Science ®Google Scholar
• Mura P, Maestrelli F, Cecchi M, Bragagni M, Almeida A. Development of a new delivery system consisting in 'drug-in cyclodextrin-in PLGA nanoparticles'. J Microencapsul 2010; 27: 479–86
   PubMed Web of Science ®Google Scholar
• Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995; 50: 924–41
   PubMed Web of Science ®Google Scholar
• Paulsson M, Edsman K. Controlled drug release from gels using surfactant aggregates: I. Effect of lipophilic interactions for a series of uncharged substances. J Pharm Sci 2001; 90: 1216–25
   Google Scholar
• Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: Application in different routes of drug administration. Acta Pharm 2005; 55: 139–56
   PubMedGoogle Scholar
• Tavornvipas S, Tajiri S, Hirayama F, Arima H, Uekama K. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone. Pharm Res 2004; 21: 2369–76
   PubMed Web of Science ®Google Scholar